394 related articles for article (PubMed ID: 30297615)
1. Gut Microbiota's Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics.
Meng X; Li S; Li Y; Gan RY; Li HB
Nutrients; 2018 Oct; 10(10):. PubMed ID: 30297615
[TBL] [Abstract][Full Text] [Related]
2. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
Lang S; Schnabl B
Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
[TBL] [Abstract][Full Text] [Related]
3. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
Boursier J; Diehl AM
Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
[TBL] [Abstract][Full Text] [Related]
6. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
7. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.
Borrelli A; Bonelli P; Tuccillo FM; Goldfine ID; Evans JL; Buonaguro FM; Mancini A
Redox Biol; 2018 May; 15():467-479. PubMed ID: 29413959
[TBL] [Abstract][Full Text] [Related]
8. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.
Bluemel S; Williams B; Knight R; Schnabl B
Am J Physiol Gastrointest Liver Physiol; 2016 Dec; 311(6):G1018-G1036. PubMed ID: 27686615
[TBL] [Abstract][Full Text] [Related]
10. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
11. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
[TBL] [Abstract][Full Text] [Related]
12. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
Ji Y; Yin Y; Sun L; Zhang W
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
[TBL] [Abstract][Full Text] [Related]
13. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.
Liu J; Yang D; Wang X; Asare PT; Zhang Q; Na L; Shao L
Front Cell Infect Microbiol; 2022; 12():774335. PubMed ID: 35444959
[TBL] [Abstract][Full Text] [Related]
14. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids.
Janssen AWF; Houben T; Katiraei S; Dijk W; Boutens L; van der Bolt N; Wang Z; Brown JM; Hazen SL; Mandard S; Shiri-Sverdlov R; Kuipers F; Willems van Dijk K; Vervoort J; Stienstra R; Hooiveld GJEJ; Kersten S
J Lipid Res; 2017 Jul; 58(7):1399-1416. PubMed ID: 28533304
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
18. Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis.
Huang SW; Ou YC; Tang KS; Yu HR; Huang LT; Tain YL; Lin IC; Sheen JM; Hou CY; Tsai CC; Tiao MM
Lipids Health Dis; 2021 Sep; 20(1):100. PubMed ID: 34496884
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Aron-Wisnewsky J; Warmbrunn MV; Nieuwdorp M; Clément K
Gastroenterology; 2020 May; 158(7):1881-1898. PubMed ID: 32044317
[TBL] [Abstract][Full Text] [Related]
20. The role of the gut microbiota in NAFLD.
Leung C; Rivera L; Furness JB; Angus PW
Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]